UY33531A - Derivados anticancerosos, su preparación y su aplicación terapéutica - Google Patents

Derivados anticancerosos, su preparación y su aplicación terapéutica

Info

Publication number
UY33531A
UY33531A UY0001033531A UY33531A UY33531A UY 33531 A UY33531 A UY 33531A UY 0001033531 A UY0001033531 A UY 0001033531A UY 33531 A UY33531 A UY 33531A UY 33531 A UY33531 A UY 33531A
Authority
UY
Uruguay
Prior art keywords
banking
derivatives
preparation
therapeutic application
alk
Prior art date
Application number
UY0001033531A
Other languages
English (en)
Inventor
Commercon Alain
Gauzy-Lazo Laurence
Philippe Hubert
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43027561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33531(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33531A publication Critical patent/UY33531A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención se refiere a compuestos de fórmula (1) en la que todos los sustituyente son tal cual se describe en detalle en la memoria descriptiva.: ------- ____ representa un enlace sencillo o un enlace doble * Uy/o U', * W y/o W', * R1, Ri, R1', Ri', * o bien R, y R2 y/o R1' y R2' Y e Y' ?M ? ALK y ALK' R y ? L1 y L2 representan conectores; ? Q ? G ? GCR1 ? Za ? Ra ? Zb ? Zb
UY0001033531A 2010-07-26 2011-07-26 Derivados anticancerosos, su preparación y su aplicación terapéutica UY33531A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1056103A FR2963007B1 (fr) 2010-07-26 2010-07-26 Derives anticancereux, leur preparation et leur application therapeutique

Publications (1)

Publication Number Publication Date
UY33531A true UY33531A (es) 2012-02-29

Family

ID=43027561

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033531A UY33531A (es) 2010-07-26 2011-07-26 Derivados anticancerosos, su preparación y su aplicación terapéutica

Country Status (30)

Country Link
US (1) US9056914B2 (es)
EP (1) EP2598507B1 (es)
JP (1) JP5814366B2 (es)
KR (1) KR20130094806A (es)
CN (1) CN103140491B (es)
AR (1) AR082341A1 (es)
AU (1) AU2011284339B2 (es)
BR (1) BR112013001978B1 (es)
CA (1) CA2806665A1 (es)
CL (1) CL2013000250A1 (es)
CO (1) CO6650375A2 (es)
CR (1) CR20130035A (es)
DO (1) DOP2013000021A (es)
EA (1) EA201390162A1 (es)
EC (1) ECSP13012404A (es)
ES (1) ES2638520T3 (es)
FR (1) FR2963007B1 (es)
GT (1) GT201300025A (es)
MA (1) MA34469B1 (es)
MX (1) MX2013001069A (es)
MY (1) MY159197A (es)
NI (1) NI201300010A (es)
NZ (1) NZ606246A (es)
PE (1) PE20130489A1 (es)
SG (1) SG187191A1 (es)
TW (1) TW201208689A (es)
UA (1) UA111164C2 (es)
UY (1) UY33531A (es)
WO (1) WO2012014147A1 (es)
ZA (1) ZA201300685B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9649390B2 (en) * 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AU2015314954B2 (en) 2014-09-12 2021-05-13 Genentech, Inc. Anti-HER2 antibodies and immunoconjugates
KR20170055521A (ko) 2014-09-17 2017-05-19 제넨테크, 인크. 항-her2 항체를 포함하는 면역콘주게이트
CA2973354A1 (en) 2015-01-14 2016-07-21 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using
JP6676058B2 (ja) 2015-01-14 2020-04-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
US9688694B2 (en) 2015-06-23 2017-06-27 Bristol-Myers Squibb Company Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CA3047683C (en) 2017-02-08 2020-03-10 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
LT3612537T (lt) 2017-04-18 2022-10-10 Medimmune Limited Pirolobenzodiazepino konjugatai
LT3668874T (lt) 2017-08-18 2022-03-25 Medimmune Limited Pirolobenzodiazepino konjugatai
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN115466231B (zh) * 2022-10-23 2024-03-08 浙江大学 管道化制备3-[2-(4-吗啉基)乙氧基]丙腈的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
JPH04502469A (ja) 1988-12-22 1992-05-07 ゾマ　コーポレイション ヒンダードカップリング剤および方法
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
ES2244210T3 (es) 1998-08-27 2005-12-01 Spirogen Limited Pirrolobenzodiazepinas.
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
WO2004043344A2 (en) 2002-11-07 2004-05-27 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
DK1651162T3 (en) 2003-05-20 2016-02-01 Immunogen Inc IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS
DE602004031239D1 (de) 2003-07-21 2011-03-10 Immunogen Inc Verfahren zu dessen anwendung
ATE516288T1 (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
RS52060B (en) * 2006-01-25 2012-04-30 Sanofi CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES
JP2009526778A (ja) * 2006-02-13 2009-07-23 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 抗腫瘍剤としてのビス−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−アントラキノン抱合体およびその製造方法
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
LT2281006T (lt) 2008-04-30 2017-11-27 Immunogen, Inc. Skersinių jungčių linkeriai ir jų panaudojimas
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
FR2939795B1 (fr) 2008-12-17 2010-12-17 Sanofi Aventis Procede de preparation d'esters actives
SG173152A1 (en) * 2009-02-05 2011-08-29 Immunogen Inc Novel benzodiazepine derivatives
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody

Also Published As

Publication number Publication date
CR20130035A (es) 2013-03-04
GT201300025A (es) 2014-07-11
CN103140491A (zh) 2013-06-05
CL2013000250A1 (es) 2013-04-12
KR20130094806A (ko) 2013-08-26
EP2598507A1 (en) 2013-06-05
WO2012014147A1 (en) 2012-02-02
EP2598507B1 (en) 2017-05-31
PE20130489A1 (es) 2013-05-08
DOP2013000021A (es) 2013-04-15
TW201208689A (en) 2012-03-01
BR112013001978B1 (pt) 2020-03-03
AU2011284339A1 (en) 2013-02-14
JP2013532680A (ja) 2013-08-19
NZ606246A (en) 2015-04-24
CA2806665A1 (en) 2012-02-02
FR2963007B1 (fr) 2013-04-05
ZA201300685B (en) 2014-10-29
JP5814366B2 (ja) 2015-11-17
FR2963007A1 (fr) 2012-01-27
UA111164C2 (uk) 2016-04-11
ECSP13012404A (es) 2013-03-28
CO6650375A2 (es) 2013-04-15
NI201300010A (es) 2013-05-13
AR082341A1 (es) 2012-11-28
US9056914B2 (en) 2015-06-16
US20130137659A1 (en) 2013-05-30
SG187191A1 (en) 2013-02-28
BR112013001978A2 (pt) 2016-05-24
MY159197A (en) 2016-12-30
MA34469B1 (fr) 2013-08-01
AU2011284339B2 (en) 2015-11-05
MX2013001069A (es) 2013-12-02
EA201390162A1 (ru) 2013-11-29
ES2638520T3 (es) 2017-10-23
CN103140491B (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
UY33531A (es) Derivados anticancerosos, su preparación y su aplicación terapéutica
CY1113727T1 (el) Παραγωγα πυριδιν-4-υλ ως ανοσορυθμιστικοι παραγοντες
CY1112465T1 (el) Παραγωγα αμινοτριαζολης ως αγωνιστες alx
SV2010003502A (es) Fungicidas novedosos
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
CO6290760A2 (es) Derivados de alcoholes de 1 fenil-2-piridinilalquilo como inbidores de la fosfodiesterasa
CR11653A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
MA32979B1 (fr) Derives aminoesterifies d'alcaloides et composition medicinale les incluant
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
EA200901612A1 (ru) Противовоспалительные соединения замещенных циклобутендионов
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
CY1114096T1 (el) Παραγωγα πυριδιν-2-υλ ως ανοσορρυθμιστικοι παραγοντες
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
CR9684A (es) Nuevos derivados de la benzoheterocicliletil carboxamida
UY32404A (es) 4-aril-butan-1,3-diamidas
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
UA107455C2 (uk) Похідні індолу як протиракові агенти

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200813